Multi-Stakeholder Approach Helped Push SPC Waiver Up The EU Agenda, Says Medicines For Europe
This article was originally published in SRA
Executive Summary
Medicines for Europe, the association that represents companies marketing generics, biosimilars and 'value-added' medicines, has called on its members to press the European Commission to introduce a manufacturing waiver for drugs still protected by a supplementary protection certificate (SPC) 'as soon as possible.'
You may also be interested in...
EC To Consult On Ways To Boost Generics & Biosimilars Industry, Introduce EU-wide SPC
A new package of measures from the European Commission will introduce an SPC export manufacturing waiver to help improve the competitiveness of Europe’s generics and biosimilars industry, while originator companies should benefit from steps to smooth out the rules on the “Bolar” research exemption and implement an EU-wide SPC.
EC To Consult On Ways To Boost Generics & Biosimilars Industry, Introduce EU-wide SPC
A new package of measures from the European Commission will introduce an SPC export manufacturing waiver to help improve the competitiveness of Europe’s generics and biosimilars industry, while originator companies should benefit from steps to smooth out the rules on the “Bolar” research exemption and implement an EU-wide SPC.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.